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Available online 15 August 2016A key response of the myocardium to stress is the secretion of factors with paracrine or endocrine function. In-
triguing in this respect is peptidase inhibitor 16 (PI16), a member of the CAP family of proteins which we
found to be highly upregulated in cardiac disease. Up to this point, the mechanism of action and physiological
function of PI16 remained elusive. Here, we show that PI16 is predominantly expressed by cardiac ﬁbroblasts,
which expose PI16 to the interstitium via a glycophosphatidylinositol (-GPI) membrane anchor. Based on a re-
ported genetic association of PI16 and plasma levels of the chemokine chemerin, we investigated whether
PI16 regulates post-translational processing of its precursor pro-chemerin. PI16-deﬁcient mice were engineered
and found to generate higher levels of processed chemerin than wildtype mice. Puriﬁed recombinant PI16 efﬁ-
ciently inhibited cathepsin K, a chemerin-activating protease, in vitro. Moreover, we show that conditioned me-
dium from PI16-overexpressing cells impaired the activation of pro-chemerin. Together, our data indicate that
PI16 suppresses chemerin activation in the myocardium and suggest that this circuit may be part of the cardiac
stress response.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Myocardial infarction, pressure overload or genetic defects of the
cardiacmuscle induce a pathologic response of themyocardium termed
cardiac remodeling. It comprises fundamental changes in gene expres-
sion and the cellular and interstitial composition of the myocardium,
among which cardiac myocyte growth (cardiac hypertrophy) and the
deposition of extracellular matrix (cardiac ﬁbrosis) are hallmarks. Car-
diac remodeling involves intense intercellular communication, wherein
secreted factors such as proteases, protease inhibitors, cytokines and
chemokines [1] or nucleotides such as extracellular cAMP [2] serve a
central role. Also, the invasion of immune cells into the impaired myo-
cardium requires local expression of chemoattractant factors [3].
By screening a cardiac cDNA library for secreted proteins, we had
previously identiﬁed peptidase inhibitor 16 (PI16) as a paracrine factor
with potential cardiac function. Whereas basal cardiac expression ofstitute of Pharmacology and
ner Strasse 29, 80802 Munich,
rdt).
. This is an open access article underPI16 is low and much surpassed by that seen in other tissues [4], a dra-
matic upregulation was found during cardiac remodeling in animal dis-
ease models and humans [4]. Up to this point, PI16 had not revealed
much of its function. One early observation about PI16 was its associa-
tion with a serum peptide termed prostatic secretory protein 94
(PSP94) [5], which is consistent with the high expression of both bind-
ing partners in the prostate gland. The role of this association and the
question in which tissue it is relevant, however, are elusive. Another
ﬁnding that has not been understood yet is that PI16 has been found
to speciﬁcally mark a subset of regulatory T cells (Treg) [6,7].
Its peptide sequence classiﬁes PI16 as a member of the CAP protein
family, the functions of which appear to be diverse and largely not un-
derstood. PI16 (alias CRISP-9) has received its name from a sequence
homology to peptidase inhibitor 15 (CRISP-8), which had been found
to inhibit trypsin [8]. Whether PI16 likewise has peptidase-inhibiting
activity remained unclear. C-terminal to the CAP domain of PI16 follows
a long peptide sequence that is predicted to be unstructured and shares
no obvious similarity to other proteins. PI16 appears in at least three
electrophoretic isoforms, each corresponding to an apparent mass that
is higher than its theoretical mass (74 kDa, 100 kDa and 108 kDa vs.
53 kDa). Glycosylation explains in part for the aberrant migration inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tion shifts all three bands to faster-migrating forms without resolving
them, see [4]). Thus, it was unclear how these isoforms are formed,
where they localize to, and with which proteins they interact.
An intriguing perspective on the function of PI16 came from a ge-
nome-wide assocation study (GWAS) that identiﬁed potential regula-
tors of chemerin levels. This study revealed correlation between a
single nucleotide polymorphism (SNP) affecting the CAP-domain of
PI16 (rs1405069) and elevated chemerin plasma levels [9]. Chemerin
(alias retinoic acid receptor responder (tazarotene induced) 2, RARRES2
or tazarotene induced gene 2, TIG2) is a ligand of chemokine-like recep-
tor 1 (CMKLR1), G protein-coupled receptor 1 (GPR1) and chemokine
receptor-like 2 (CCRL2), but only CMKLR1 appears to be activated by
chemerin binding [10]. Chemerin exists in various isoforms that are
generated by proteolytic cleavage of pro-chemerin. Several proteases
have been shown to catalyze this activating step, whereas others were
found to inactivate chemerin [10,11]. A synthetic peptide that had
been delineated from chemerin (but does not seem to occur in nature)
was found to be immunosuppressive and had been envisaged as a po-
tential anti-inﬂammatory therapeutic. Two of the three chemerin re-
ceptors, GPR1 and CCRL2, appear to be silent receptors with presumed
decoy function [12,13]. These ﬁndings in sum support the idea that
chemerin may have both, pro- and anti-inﬂammatory functions. With
respect to cardiac function, the pro-inﬂammatory CMKLR1 receptor is
expressed by cardiac cells [14] and chemerin serum levels seem to cor-
relate with dilated cardiomyopathy [15]. Together, these ﬁndings un-
derscore the possibility that PI16 and chemerin are functionally
coupled in the heart.
In this study, we asked whether peptidase inhibitor 16 (PI16) has a
function in chemokine regulation in myocardium. We pursued this hy-
pothesis by analyzing the expression of PI16, its association with and
the processing of chemerin in wildtype and PI16-deﬁcient mice, and
tested for the impact of PI16 on chemerin receptor activation. Our
data show that PI16 represses posttranslational processing of pro-
chemerin, thereby controlling chemerin levels and signaling in the
myocardium.
2. Results
2.1. PI16 is secreted by cardiac ﬁbroblasts and tethers to their membrane
via a GPI anchor
To approach the cardiac function of PI16, we generated amouse line
that is globally deﬁcient of the PI16 gene. A PCR product was ampliﬁed
that comprised neomycin cDNAwith ﬂanking frt sites, upstream of mu-
rine PI16 exons3 to 4, and further framed by loxP sites. This productwas
cloned into a targeting vector for the transfection of mouse embyronic
stem cells, and neomycin was used for selection. PI16ﬂoxneo mice carry-
ing this insert were then crossed with a mouse line that encodes Flp
recombinase to delete the neomycin cassette, and genetically conﬁrmed
offspring were then crossed with transgenic mice that express Cre
recombinase under the control of the nestin promoter. The PI16−/− ge-
notype (due to deletion of exons 3 to 4) was conﬁrmed by Southern
blotting (Fig. A.1). Under conditions that provoke strong upregulation
of PI16 in wildtype mice, e.g. transverse aortic constriction (TAC), the
Pi16−/−×mice were still devoid of the protein (Fig. 1A), thus further
conﬁrming successful genetic deletion.
PI16−/−micedid not display anobvious phenotype under basal con-
ditions, as litter size, gender distribution and also basal blood parame-
ters (recorded 1, 3, 5 and 8 months after birth) were similar to
wildtype controls (Fig. A.2 and Table A). Furthermore, analysis of the
ratio between heart weight and body weight (HW/BW) and the extent
of extracellular matrix formed were not changed in 8 months-old
PI16−/−mice compared to controls, indicating that neighter cardiac hy-
pertrophy nor ﬁbrosis were induced by the absence of PI16 under basal
conditions (Fig. A.3). Remarkably, application of TAC to PI16−/− micelikewise did not confer a phenotypewithin 28 d after surgery, as judged
from the abovementioned parameters and from additional criteria for
myocardial morphology and function (Fig. A.4). This ﬁnding was some-
what suprising in view of the strong upregulation of PI16 expression in
this disease model. It is possible that constitutive deletion of the PI16
gene provokes compensatory expression of other genes, as has been ob-
served inmany cases [16]. It is also possible that the TACmodelmay not
fully address the function of PI16 (see discussion).
To further approach the function of secreted PI16, we investigated
where the protein localizes within the myocardium. Stainings of left
ventricular sections revealed islet-like deposits in the interstitial extra-
cellular space, which increased in number and size under TAC (Fig.
1B). We then asked whether cardiac cells endogenously express PI16
and, if so, in which of these it predominates. For this, we collected
cells from left ventricular tissue of wildtype mice by Langendorff perfu-
sion, sorted them by FACS for the presence of speciﬁc surface markers,
and quantiﬁed PI16 mRNA therein by qPCR. This approach identiﬁed
the cardiac ﬁbroblast (PDGFR+ cells) as the main source of
intramyocardial PI16, whereas 6- to 11-fold lower levels were found
in cardiac myocytes, leukocytes (CD45+ cells), endothelial cells
(CD105+ cells) and others (Fig. 1C). Thus, although PI16 exists in cardi-
acmyocytes and, as reported earlier [4], is able tomodulate their hyper-
trophic response in vitro, the dominant cardiac function of PI16 may
originate from the cardiac ﬁbroblast.
Remarkably, bioinformatic analysis (http://mendel.imp.ac.at/sat/
gpi; [17]) predicts the presence of a glycophosphatidylinositol- (GPI)-
anchor attachment site at position 466 of the primary 489 residues-
long murine PI16 protein (Fig. 1D). As GPI anchoring sites are deter-
mined by sequence context rather than by a speciﬁc consensus motif,
their recognition requires complex algorithms and necessitates experi-
mental validation. First experimental support for the GPI anchor in PI16
came from our ﬁnding that overexpression of PI16 in CHO cells en-
hanced detection of the protein on the cell membrane (Fig. B.1). To val-
idate this further, cells were incubated with phospholipase C (PLC) to
cleave PI16 at the GPI anchor. HEK293 cells, transiently transfected
with a PI16 expression construct, were incubated in the presence or ab-
sence of PLC. Afterwards, cell-free supernatant was collected, cells were
washed, and the fractions analysed by Western blotting using an anti-
PI16 antibody. Conditioned medium from non-digested cells was load-
ed as a control. The analysis showed that the lysate of PLC-treated
cells was devoid of PI16-bands that correspond to higher molecular
mass, in favor of a band that appeared in the supernatant of these
cells and corresponded to the main band observed in conditioned
medium of control cells (Fig. 1E). In analogy to the effects exerted
by PLC, deletion of the sequence that determines GPI-anchoring of
PI16 (peptide positions 466–489) resulted in a pronounced PI16
band in the culture supernatant (Fig. B.2). Together, these data pro-
vide evidence for a functional GPI anchor that tethers PI16 to the
cell membrane.
2.2. Secreted PI16 interacts with the chemokine chemerin
The intriguing genomic association between PI16 and chemerin
[9], together with our experimental data on PI16, led us to ask
whether chemerin is present in cardiac tissue and, if so, whether it
is physically associated with PI16. Quantitative PCR analysis in
FACS-sorted cells from mouse myocardium indeed showed an ex-
pression pattern of chemerin (RARRES2) similar to that observed
for PI16, i.e. more prominent expression in cardiac ﬁbroblasts than
in the other cell types analysed (Fig. 2A). Consistent with the pro-
posed function of chemerin, leukocytes also exhibited pronounced
chemerin expression, yet to much lower extent than in cardiac ﬁbro-
blasts (Fig. 2A).
Next, endogenous PI16was immunoprecipitated using speciﬁc anti-
bodies, immobilized on protein A resin, and analysed on blots using spe-
ciﬁc antibodies for PI16 and chemerin, respectively. Indeed, both
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Fig. 1. PI16 is secreted by cardiac ﬁbroblasts and tethers to theirmembrane via a GPI anchor. (A)Western blot analysis of PI16 inmousemyocardial tissue lysates, conﬁrming TAC-induced
upregulation of PI16 in wildtype mice (PI16+/+) and global Pi16 deﬁciency in offspring from PI16−/− × Cre crossings. GAPDH detection served as loading control. Arrows indicate
previously described PI16 variants. (B) Immunohistochemical staining of PI16 and Gomori-Masson counterstaining in myocardium from wildtype (PI16+/+) or PI16−/− mice,
subjected to transverse aortic constriction (TAC). Sham-operated mice served as controls. (C) Quantitative PCR analysis of Pi16mRNA in FACS-isolated primary cells from myocardium
(ﬁbroblasts sorted for PDGFRa, leukocytes for CD45, endothelial cells for CD105). Cells that were not positive for these markers were assigned as others. Myocytes were separated
ahead of FACS by centrifugation (n = 4–7). Data are mean ± s.e.m. and are analysed using 1-way ANOVA with Bonferroni post-test. (D) Schematic structure of murine PI16,
highlighting the CAP domain and the predicted GPI anchor attachment site, followed by a hydrophobic co-determinant of the anchor motif. (E) Immunoblot analysis for PI16 after
phospholipase C (PLC) cleavage of the GPI anchor, demonstrating functionality of the latter. PI16 from lysed cells and cell-free supernatant was normalized to GAPDH (n= 4).
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ative control only showed a faint chemerin band (Fig. 2B). Consistently,
transfection of HEK293 cells with plasmid constructs for murine full-
length PI16 and pro-chemerin (mChem162) allowed for efﬁcient co-im-
munoprecipitation of both proteins (Fig. 2C).
Elevation of chemerin in humans, due to a SNP in the PI16 gene [9],
prompted us to askwhether genetic deletion of PI16 inmicewould alter
the level of chemerin. Indeed, we found total chemerin protein 29%
lower in PI16-deﬁcient mice than in corresponding littermate controls(Fig. 2D). Since this ELISA could not discriminate betweenpro-chemerin
and its processed forms, we fractionated myocardial cell lysates from
wildtype and PI16−/− mice by SDS-PAGE and tested for chemerin on
Western blots. A band that corresponds to the product(s) of pro-
chemerin processing appeared more prominent in lysates from
PI16−/− background than in wildtype (Fig. 2E). Of note, we also ob-
served this impact on chemerin processing in adipose tissue (Fig. C),
which naturally strongly expresses chemerin [18] and PI16 [4] and
which is thought to be a site of chemerin function, too. Together, these
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ated with chemerin.
2.3. PI16 inhibits the (pro-)chemerin-processing protease cathepsin K
To test for the suspected protease-inhibiting function of PI16, two
different experimental strategies were applied, using the PI16 con-
structs depicted in Fig. 3A. First, we analysed whether puriﬁed PI16 in-
terfered with the activity of cathepsin K, a natural chemerin-activating
protease [19]. CHO cells were stably transfected with a construct for
the expression of a PI16 variant that lacked the GPI-anchoring motif
(PI16-ΔGPI-Fc), but was expressed in fusion to a human IgG Fc se-
quence. PI16 was isolated from cell culture supernatant upon binding
to protein A resin, eluted by glycine pH shock (assuming that the large
fraction of cysteines preserves structure and activity of PI16) and after-
wards buffered to pH 7.
Addition of puriﬁed PI16 to a colorimetric assay for cathepsin K ac-
tivity revealed dose-dependent inibition of cathepsin K. In this assay,
0.3 μg PI16 achieved inhibition of cathepsin K, as seen alsowith the syn-
thetic cysteine protease inhibitor E-64 (Fig. 3B). A 10-fold larger amount
of puriﬁed Fc fragment, used as a negative control, had only little effect
on the assay (Fig. 3B).
2.4. PI16 suppresses chemerin-dependent activation of the chemokine re-
ceptor CMKLR1
The second approach we devised is based on the rationale that se-
creted PI16 would be able to condition a culture medium such that itblocks the processing of pro-chemerin and thereby reduces the extent
of chemerin-dependent receptor activation. As a readout for the latter,
we measured β-arrestin2 recruitment by the chemerin receptor using
ﬂuorescence resonance energy transfer (FRET) (see Fig. 3C for experi-
mental principle). HEK293-cells were transfected with two constructs
encoding murine pro-chemerin and PI16-ΔGPI-Fc, respectively, and,
the cell-free supernatant was transferred after 48 h to sensor cells that
had been transfected with CMKLR1-CFP and a β-Arrestin2-YFP-fusion
construct. Bothﬂuorophoreswere expressed in their expected compart-
ments (Fig. 3C) and ligand-dependent YFP-β-Arrestin2 recruitment to
CMKLR1 was well detectable (documented by normalized FRET ratio
YFP535/CFP480) (Fig. 3D). Importantly, supernatant from donor cells
co-transfected with PI16 (next to pro-chemerin) signiﬁcantly reduced
CMKLR1 activation in sensor cells (Fig. 3E). Thus, both experimental
strategies support the conclusion that PI16, by inhibiting proteolytic ac-
tivation of pro-chemerin, obstructs signaling of this chemokine to other
cells. We believe that the PI16-chemerin-CMKLR1-axis is a self-sufﬁ-
cient entity in the myocardium, which prevents overshooting of
chemerin-induced responses in the injured myocardium. Examination
of this scenario should be subject to upcoming studies.3. Conclusions and discussion
In this study, we characterized PI16, a protein that is strongly upreg-
ulated in diseasedmyocardium.We provide evidence for PI16 secretion
by cardiac ﬁbroblasts, its extracellular tethering to their membrane, and
its ability to inhibit proteolytic activation of the chemokine chemerin.
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61M. Regn et al. / Journal of Molecular and Cellular Cardiology 99 (2016) 57–64Supported by genetic evidence that suggested a link between PI16
and chemerin, our data indicate that themyocardium is a self-sufﬁcient
entity for PI16-regulated processing of chemerin and that this circuit
may be important in cardiac disease. We propose a model (Fig. 4) in
which cardiacﬁbroblasts express PI16 and present it to the extracellular
space through the GPI anchor moiety. As reported for many other pro-
teins, this anchoringmay be an intermediate step before PI16 is liberat-
ed by phospholipase activity. PI16 inhibits proteolytic processing of pro-
chemerin, thereby preventing its activation. Through this mechanism,
less chemerin is available to activate the receptor CMKLR1, whichengages signaling towards chemotaxis [10]. Interferencewith chemerin
signaling by PI16 should thus lead to reduced pro-inﬂammatory activa-
tion of leukocytes.
We do, at present, not know which of the processed chemerin vari-
ants is elevated in PI16-deﬁcient mice, since the similar masses of these
variants obstruct a differentiating analysis. The ability of PI16 to prevent
chemerin-dependent CMKLR1 receptor activation argues in favor of the
idea that PI16 inhibits the formation of active chemerin variants (corre-
sponding to human Chem158, Chem157 and/or Chem156). In line with
this, recombinant PI16 inhibited cathepsin K, a protease that activates
Chemerin-sensitive
cell 
Pro-chemerin Chemerin
Protease
(cleaved)
PI16
GPI
PI16
CMKLR1
Pro-inflammatory
responsePro-chemerin
Cardiac Fibroblast
PI16
Fig. 4. Schematic model, illustrating the proposed role of PI16 in cardiac chemokine signaling: PI16 and pro-chemerin are expressed and secreted by cardiac ﬁbroblasts. PI16 tethers to its
expressing cell via its GPI anchor. In the interstitium, secreted PI16 inhibits proteolytic activation of (pro-)chemerin and thereby prevents chemerin-dependent activation of the G protein-
coupled receptor CMKLR1 and subsequent pro-inﬂammatory pathways.
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teases that inactivate chemerin [12], thereby raising the level of active
chemerin. Interestingly elaﬁn, an endogenous inhibitor of elastase
(which, among other substrates, also processes pro-chemerin), has
been related to cardiac injury after myocardial ischemia [20]. This em-
phasizes how profound the impact of endogenous peptidase inhibitors
on cardiac function may be.
An important issue that future studies need to resolve is under
which conditions PI16 upregulation modulates immune cell recruit-
ment by chemerin. This may also explain why PI16 deﬁciency did not
alter the response to TAC, but leaves open why wildtype mice upregu-
late PI16 in this disease setting. Our experimental model of transverse
aortic constriction, which boosts PI16 expression, did not resolve this
question, since these disease conditions favor cardiac remodeling rather
than inﬂammation. Other than observed for PI16, TAC conditions do not
seem to alter chemerin gene expression (data not shown). Interestingly,
chemerin levels had recently been found to be elevated in heart failure
patients [15]. It thus seems possible that certain cardiac conditions will
reveal a pathologic interdependence of PI16 and chemerin.
Chemerin is expressed in many tissues, with adipose tissue, adrenal
gland, liver, pancreas and reproductive system ranking high (www.
ensembl.org). As a ligand of the chemokine receptor CMKLR1, chemerin
is able to recruit macrophages and dendritic cells to adipose tissue [21].
Although the chemoattractant role of chemerin stands without doubt,
other studies also suggested functions in fatty acid metabolism and glu-
cose homeostasis, i.e. key aspects of themetabolic syndrome [10,11,22].
Chemerin-deﬁcient mice are asymptomatic, but they show elevated
blood glucose and impaired insulin regulation. These mice were also re-
ported to have higher serum levels of non-esterized fatty acids, consis-
tent with a role in lipolysis. High expression of chemerin in adipose
tissue parallels intriguingly the high basal expression of PI16 in fat
cells. Interestingly, the role of epicardial adipose tissue in cardiac disease
is increasingly appreciated [23]. It would thus not be surprising if, in ad-
dition to a direct intramyocardial axis between PI16 and chemerin, both
would also inﬂuence cardiac function through their activities in epicar-
dial fat tissue.Webelieve that the data presented here provide a basis to
pursue this hypothesis.
4. Materials and methods
4.1. Quantitative real-time PCR
Total RNA was prepared using PeqGOLD RNApure (Peqlab) accord-
ing to the manufacturer's protocol. 500 ng RNA were reverse-tran-
scribed using the Protoscript II cDNA Synthesis Kit (NEB, procedure
according to manufacturer's protocol). Quantitative PCR analysis was
conducted using the Fast Start SybrGreen MasterMix according to the
standard protocol (Roche). The dissociation curve of the primers was
monitored to control for primer speciﬁcity. Sample volume was
12.5 μl, containing 6.25 μl SybrGreen MasterMix, 400 pM primers and
10 ng template DNA. Primer sequences for real-time PCR were (genesymbols and species followed by sequences of forward and reverse
primers):
Pi16 forward: 5′-CCAGTGCCCTCTTGGCTAC-3′
Pi16 reverse: 5′-ACCTCGGTCACCCTTGGA-3′
RARRES2 (chemerin) forward: 5′-GTGCACAATCAAACCAAACG-3′
RARRES2 reverse: 5′-GGCAAACTGTCCAGGTAGGA-3′
Actb forward: 5′-GCAGCTCCTTCGTTGCCGGT-3′
Actb reverse: 5′-TACAGCCCGGGGAGCATCGT-3′.
4.2. Cloning of plasmid vectors for expression
For expression in HEK293 and CHO cells murine Pi16 and murine
pro-chemerin cDNAs were cloned into the pT-Rex-DEST 30 vector
(Invitrogen). For fusion of the murine Pi16 sequence to hIgG1-Fc, the
pFUSE-hIgG1-Fc vector (InvivoGen) was used. Pi16 was ampliﬁed by
PCR with the following primers to delete the GPI-attachment site at
the C-terminus and insert a tobacco etch virus protease cleavage site.
Pi16 forward: 5′-AAAAAAGGCGCCCGAGCCCATCAACAAGTTTG-3′.
Pi16 reverse: 5′-AAAAAAGCTCGAGATCGATTGGAAGTAGAGGTTCT
CCTTCAAATCCCAGTCGGCC-3′.
4.3. Preparation of primary cardiac cells from mice, and FACS procedure
Cells were isolated from wildtype (PI16+/+) and PI16−/− mice as
described earlier [2]. In brief, hearts were explanted and perfused in
buffer A (113 mM NaCl, 4.7 mM KCl, 0.6 mM KH2PO4, 0.6 mM
Na2HPO4, 1.2 mM MgSO4, 12 mM NaHCO3, 10 mM KHCO3, 10 mM
HEPES, 32 μM Phenol Red, 30 mM taurine) in the presence of collage-
nase II. After dissociation andmechanical distortion of the tissue, cardiac
myocytes were allowed to settle, before the pellet was resuspended in
buffer B (47.5ml of buffer A, 2.5ml FCS, 10mMCaCl2). After 10min sed-
imentation non-myocyte cells were pelleted from the supernatant and
then staining with different cell type speciﬁc surface markers for cell
sorting (CD45 for leukocytes, CD105 for endothelial cells, PDGFRa for ﬁ-
broblasts) was performed. FACS was performed using a BioRad S3 cell
sorter. The isolated cells were then cryoconserved at −80 °C and
RNA-isolation followed as described above.
4.4. Immunoprecipitation from murine plasma and cell culture medium
Murine plasma from PI16+/+ mice was diluted 1:10 in lysis-buffer
before 10 μg of anti-chemerin antibody were added (for the negative
control IP antibody was omitted), and the samples were incubated
over night at 4 °C in a head-over-toe shaker. 20 μl Protein G resin
(Dynabeads, Invitrogen) was added, and the mixture was incubated at
room temperature for 2 h while shaking. After three washing steps
with PBS, samples were resuspended in denaturing sample buffer,
boiled for 10 min, and loaded onto a 15% SDS-polyacrylamide gel. For
immunoprecipitation from cell culture medium, 500 μl of the medium
was used. After incubation over night at 4 °C with 10 μg anti-PI16
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munoprecipitation from plasma.
4.5. Western blot analysis
Lysates from tissue or cultured cells were fractionated by SDS-PAGE
(8 or 15% polyacyrylamide) and blotted according to standard proce-
dures. Primary antibodies againstmurine PI16 [4] andmurine chemerin
(R&DSystemsAF2352)were diluted 1:1000, secondary antibodieswere
anti-rabbit, anti-mouse and anti-goat (diluted 1:10,000 in PBS + 0.5%
Tween20). Chemiluminescence was quantiﬁed by Multi-Gauge image
analysis software (Fujiﬁlm) and normalized to signals of GAPDH
protein.
4.6. Immunohistochemistry and immunoﬂuorescence staining
Myocardial tissues from PI16+/+ and PI16−/−micewere snapfrozen
and ﬁxed with formalin, embedded in parafﬁn, cut, and stained with
haematoxylin and eosin. Immunohistochemistry (IHC) was performed
with an automated immunostainer (Discovery® Xt, Roche) using pro-
tein A-puriﬁed rabbit polyclonal antibody (20 ng/μl) against exon 5-
ecoded, puriﬁed PI16 peptide. Heat-induced antigen retrieval in 5%
EDTA pH 8 buffer was used and Gomori-Masson staining was per-
formed after IHC. To detect PI16 in transfected CHO cells, cells were
ﬁxed with 4% paraformaldehyde, incubated with an anti-PI16 antibody
(1:100 dilution) and detected by Alexa 568-conjugated anti-rabbit-IgG
secondary antibody (Life Technologies). Cells were subsequently em-
bedded in Vectashield (Vector labs) and images were taken with a
Leica TCS SP5 Confocal microscope.
4.7. FRET measurements
HEK293 cells were transfected with constructs encoding murine
pro-chemerin and PI16-ΔGPI-Fc, and cultured in DMEM/10% FCS. The
supernatant was collected 48 h after transfection and transferred onto
CMKLR1-sensor cells (HEK293 cells co-transfected with plasmids
encoding CMKLR1-CFP and YFP-β-Arrestin2, 48 h previous to treatment
with conditionedmedium). FRETwasmeasured as previously described
[24], using a Zeiss Axio Observer Z1 invertedmicroscope equippedwith
DualView2 and an Evolve camera (Photometrics). The emission intensi-
ty of CFP (at 480 ± 20 nm) and YFP (at 535 ± 15 nm) were recorded
upon excitation at 436 nmusing theMetaﬂuor software (Molecular De-
vices). The recorded YFP signal was corrected for spillover of CFP and
data were analysed with Prism 6 (GraphPad Software).
4.8. PI16 puriﬁcation
Plasmid vectors for fusion constructs ofmouse Pi16 and a human IgG
Fc fragment (see above for primers and host vectors, and Fig. 3 for sche-
matic drawing) were stably transfected in CHO cells using Lipofecta-
mine 2000 (Life technologies, procedure according to manufacturer).
Positive clones were selected by resistance to Zeocin (400 μg/ml;
InvivoGen). After positive expression control (on Western blots), 2 l of
cell culture medium were collected and passed through 1 ml Protein A
resin (HiTrap Protein A HP, GE Healthcare) for approx. 30 h at 4 °C at
a ﬂow rate of 1ml/min. After several washings with 10ml of 20mM so-
diumphosphate, proteinswere eluted by 100mMglycine, pH 3 and im-
mediately neutralized in 500 μl 1MTris pH=8.5. Protein concentration
was determined according to absorbance at 280 nm.
4.9. Chemerin ELISA in plasma
Chemerin was quantiﬁed in plasma from PI16+/+ and PI16−/−mice
using the Mouse Chemerin Quantikine ELISA Kit (R&D Systems). 10 μl
plasma from heparinized blood were used and processed according to
the manufacturer's protocol. Measurement was carried out in a TecanInﬁnite 200 multiplate reader at 450 nm with wavelength correction
at 540 nm.
4.10. Phospholipase C cleavage assay
HEK293 cells were transiently transfected with a plasmid construct
for full-length murine PI16 (using Lipofectamine 2000, Life Technolo-
gies). 48 h after transfection, cell-free mediumwas collected for further
analysis and cells were washed with PBS. Thereafter, 0.1 units of phos-
pholipase C (Invitrogen) in PBS was added to the cells and incubated
for 20 min at 37 °C. Cells and cell-free supernatants were analysed by
SDS-PAGE.
4.11. Protein lysates
Lysates from tissue or from cultured cells were prepared using 2%
SDS lysis buffer (50 mM Tris, 1 mM NaVO4, 2% m/v SDS). Frozen tissue
was mechanically homogenized in this lysis buffer. After incubation
with benzonase (5% (v/v) ﬁnal concentration), tissues were further
distorted by soniﬁcation for 10 min. Afterwards, protein concentration
was measured by Pierce BCA protein assay (Life Technologies) and di-
luted to 1 μg/μl in 2% SDS lysis buffer for SDS-PAGE.
4.12. Targeted gene disruption of murine Pi16 locus
The targeting vector for the PI16 locus was designed to target exons
3 and 4 ofmurine PI16,ﬂanking itwith loxP sites for targeted deletion of
PI16. The construct was ﬁrst ampliﬁed in bacteria, then linearized and
electroporated in embryonic stem cells (ES-cells (Nagy R1 clone, pas-
sage 13 [25]). Clones were selected for neomycin resistance (encoded
by the targeting construct) and veriﬁed by PCR and Southern Blot
using the primers forward 5′-GAATTCGATAACTGCAGATATAAC-3′ and
reverse 5′-CACAGCGCATACAAGGATGG-3′. The reverse primer was
also used as a Southern blot probe. Veriﬁed clones were expanded and
injected into blastocysts of the SV129 mouse line, leading to chimeric
mice that carried themodiﬁed Pi16-allele in their germ line. After cross-
ing thesemicewithwildtype C57BL/6Nmice, genomic DNA from tail bi-
opsies was screened for insertion of the neomycin targeting cassette
using the primers LoxpF 5′-GACAGATTCCATCCTTAAGTCCC-3′ and
LoxpR 5′- CCCGGCCACGGGCCCTTCGCAC-3′. A band that corresponds
to 249 bp was observed inmice carrying the neomycin cassette, where-
as a shorter product (88 bp) was detected in wild-type mice. After
crossing Pi16ﬂoxneo mice with Actb-Flp mice and nestin-Cre mice, global
genetic deletion of the Pi16-exons 3 and 4 was conﬁrmed in a three-
primer-PCR (5′ﬂloxp1: 5′- ACCAACCAACCGAATAACCA-3′, LoxpF: 5′-
GACAGATTCCATCCTTAAGTCCC-3′, Delloxp4R: 5′- TCCGCTTAGAGG
ACTGCCTA-3′) that generated a band of 341 bp in the genetically mod-
iﬁed mice and a band of 146 bp in wildtype mice.
4.13. In vitro protease assay
In an assay for cathepsin K activity (BioVision), 0.02 mU recombi-
nant cathepsin K was incubated with 0.01 mM substrate (Z-Gly-Pro-
Arg-AMC (Peptanova)) with or without the denoted concentrations of
puriﬁed PI16-ΔGPI-Fc. The assay was carried out in 100 μl (in 50 mM
NaOac, pH = 5.5, 2.5 mM EDTA, 1 mM DTT, 0.01% Triton X-100). As a
positive control for the inhibition of cathepsin K, E-64 was applied
( 0.1 mM). Substrate turnover was monitored upon absorbance at
370 nm in a Tecan multiplate reader inﬁnite 200, and normalized to a
control without protease inhibitor.
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